Autophagic degradation of epidermal growth factor receptor in gefitinib-resistant lung cancer by celastrol

Int J Oncol. 2016 Oct;49(4):1576-88. doi: 10.3892/ijo.2016.3644. Epub 2016 Aug 3.

Abstract

Drug resistance of non-small cell lung cancer (NSCLC) is highly correlated to the mutation of the epidermal growth factor receptor (EGFR). Although EGFR tyrosine kinase inhibitors (TKIs) are available clinically, the molecular complexity of NSCLC has made it necessary to search for alternative therapeutic approaches to overcome the drug resistance of NSCLC. In the present study, we identified a triterpene molecule derived from the herbal plant Tripterygium wilfordii, celastrol, as a novel autophagy inducer. We demonstrate that celastrol exhibited selective cytotoxic effect towards EGFR mutant NSCLCs. In addition, celastrol also facilitated the autophagic degradation of Hsp90 client protein including EGFR and Akt on both EGFR wild-type and mutant NSCLCs via calcium-mediated autophagy. Blockage of celastrol-induced autophagic degradation of EGFR by autophagic inhibitor or calcium chelator decreased celastrol-mediated cell death in gefitinib-resistant NSCLCs. Overall, our findings suggest that celastrol may be developed as an effective anticancer agent for treatment of gefitinib-resistant NSCLC in the future.

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Autophagy / drug effects*
  • Blotting, Western
  • Cell Survival / drug effects
  • Drug Resistance, Neoplasm / drug effects*
  • ErbB Receptors / drug effects
  • ErbB Receptors / metabolism*
  • Flow Cytometry
  • Gefitinib
  • Humans
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / metabolism
  • Lung Neoplasms / pathology*
  • Pentacyclic Triterpenes
  • Proteolysis / drug effects
  • Quinazolines / pharmacology*
  • Reverse Transcriptase Polymerase Chain Reaction
  • Triterpenes / pharmacology*
  • Tumor Cells, Cultured

Substances

  • Antineoplastic Agents
  • Pentacyclic Triterpenes
  • Quinazolines
  • Triterpenes
  • EGFR protein, human
  • ErbB Receptors
  • celastrol
  • Gefitinib